Genmab A/S (GMAB) News
NASDAQ: GMABHealth CareBiotechnology: Pharmaceutical PreparationsUSD
37.07+1.02 (+2.83%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
GMAB news summary
We found 4 recent headlines mentioning Genmab A/S (GMAB): 4 in the past week and 4 in the past 30 days, most often from Nasdaq. For price context, GMAB is up 2.83% at $37.07. The most recent story, "Weekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data", was published by Nasdaq on Oct 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Genmab A/S headlines
- Weekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data(RTTNews) - This week, biopharmaceutical companies saw a busy week of regulatory decisions, strategic partnerships and clinical developments, alongside pipeline setbacks and workforce reductions.NasdaqABBV, ALVO, ARGX, BBIO
- AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCLABBV's epcoritamab plus R-CHOP cut progression or death risk by 51% in frontline DLBCL, meeting the phase III study's PFS goal.NasdaqABBV, GMAB, PFE, FRO
- AbbVie, Genmab's Epcoritamab Plus R-CHOP Improves PFS & Cuts Progression Risk In Lymphoma(RTTNews) - AbbVie (ABBV) and Genmab (GMAB) reported positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating epcoritamab plus R-CHOP in patients with newly diagnosed diffuse large…NasdaqABBV, GMAB
- AbbVie, Genmab's Epcoritamab Plus R-CHOP Improves PFS In DLBCL(RTTNews) - AbbVie (ABBV) and Genmab (GMAB) reported positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating epcoritamab plus R-CHOP in patients with newly diagnosed diffuse large…NasdaqABBV, GMAB